Literature DB >> 33988889

The emerging role of microRNA in regulating the mTOR signaling pathway in immune and inflammatory responses.

Nazanin Nazari1, Farzaneh Jafari2, Ghasem Ghalamfarsa3, Abolghasem Hadinia3, Amir Atapour4, Majid Ahmadi5, Sanam Dolati6, Davood Rostamzadeh3,7.   

Abstract

The mechanistic/mammalian target of rapamycin (mTOR) is considered to be an atypical protein kinase that plays a critical role in integrating different cellular and environmental inputs in the form of growth factors, nutrients and energy and, subsequently, in regulating different cellular events, including cell metabolism, survival, homeostasis, growth and cellular differentiation. Immunologically, mTOR is a critical regulator of immune function through integrating numerous signals from the immune microenvironment, which coordinates the functions of immune cells and T cell fate decisions. The crucial role of mTOR in immune responses has been lately even more appreciated. MicroRNAs (miRNAs) are endogenous, small, noncoding single-stranded RNAs that act as molecular regulators involved in multiple processes during immune cells development, homeostasis, activation and effector polarization. Several studies have recently indicated that a range of miRNAs are involved in regulating the phosphoinositide 3-kinase/protein kinase B/mTOR (PI3K/AKT/mTOR) signaling pathway by targeting multiple components of this signaling pathway and modulating the expression and function of these targets. Current evidence has revealed the interplay between miRNAs and the mTOR pathway circuits in various immune cell types. The expression of individual miRNA can affect the function of mTOR signaling to determine the cell fate decisions in immune responses through coordinating immune signaling and cell metabolism. Dysregulation of the mTOR pathway/miRNAs crosstalk has been reported in cancers and various immune-related diseases. Thus, expression profiles of dysregulated miRNAs could influence the mTOR pathway, resulting in the promotion of aberrant immunity. This review summarizes the latest information regarding the reciprocal role of the mTOR signaling pathway and miRNAs in orchestrating immune responses.
© 2021 Australian and New Zealand Society for Immunology, Inc.

Entities:  

Keywords:  AKT; PTEN; immune response; mTOR signaling; microRNAs

Year:  2021        PMID: 33988889     DOI: 10.1111/imcb.12477

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  4 in total

Review 1.  mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.

Authors:  Sahar Mafi; Behzad Mansoori; Shahram Taeb; Hossein Sadeghi; Reza Abbasi; William C Cho; Davoud Rostamzadeh
Journal:  Front Immunol       Date:  2022-02-18       Impact factor: 7.561

2.  Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy.

Authors:  Benjamin D Varco-Merth; William Brantley; Alejandra Marenco; Derick D Duell; Devin N Fachko; Brian Richardson; Kathleen Busman-Sahay; Danica Shao; Walter Flores; Kathleen Engelman; Yoshinori Fukazawa; Scott W Wong; Rebecca L Skalsky; Jeremy Smedley; Michael K Axthelm; Jeffrey D Lifson; Jacob D Estes; Paul T Edlefsen; Louis J Picker; Cheryl Ma Cameron; Timothy J Henrich; Afam A Okoye
Journal:  J Clin Invest       Date:  2022-05-16       Impact factor: 19.456

3.  Identifying novel SMYD3 interactors on the trail of cancer hallmarks.

Authors:  Candida Fasano; Martina Lepore Signorile; Katia De Marco; Giovanna Forte; Paola Sanese; Valentina Grossi; Cristiano Simone
Journal:  Comput Struct Biotechnol J       Date:  2022-04-11       Impact factor: 6.155

4.  Extracellular vesicles derived from Trichinella Spiralis larvae promote the polarization of macrophages to M2b type and inhibit the activation of fibroblasts.

Authors:  Ji Wu; Yao Liao; Dinghao Li; Zifeng Zhu; Lichao Zhang; Zhongdao Wu; Ping He; Lifu Wang
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.